Therapeutic Exosomes for Rare Cancers: Advances and Clinical Translation.

WHY IT MATTERS

Patients with rare cancers often lack targeted treatments and face delayed diagnoses—exosome-based therapies could provide new options by delivering drugs more effectively to tumors while causing fewer side effects.

Scientists are developing tiny particles called exosomes that can deliver cancer-fighting medicines directly to rare cancer tumors. These natural particles act like delivery trucks, carrying drugs to cancer cells while reducing damage to healthy cells. Early research shows this approach could help rare cancer patients who currently have few treatment options.

Therapeutic Exosomes for Rare Cancers: Advances and Clinical Translation. Abstract: Rare cancers collectively account for a proportion of cancer-related morbidity and mortality, and patients face significant challenges, including delayed diagnosis, lack of targeted therapies, and poor clinical outcomes. Exosome-based therapies have emerged as promising tools to address these unmet needs. Exosomes, naturally secreted extracellular vesicles, are increasingly engineered as nanocarriers for the targeted delivery of chemotherapeutics, nucleic acids, and immune modulators. Their ability to modulate the tumor microenvironment, influence immune responses, and overcome drug resistance makes them especially attractive. In rare cancers, preliminary studies have demonstrated the utility of exosomes in improving tumor specificity, enhancing payload stability, and reducing systemic tox Authors: Unnikrishnan et al. Journal: ChemMedChem MeSH: Humans, Exosomes, Neoplasms, Antineoplastic Agents, Rare Diseases, Tumor Microenvironment, Animals